Keywords: fda, notes, risk, infection, rates, ra, drugs

FDA notes risk of infection rates with RA drugs are outweighed by benefits

Article | 20 August 2001

Print This

At the same time as the US Food and Drug Administration's ArthritisDrugs Advisory Committee was recommending approval of Amgen's rheumatoid ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in